A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisFrederik Nevens, Д. А. Шапиро, Roya Hooshmand-Rad et al.|New England Journal of Medicine|2016Cited by 1.1k
Targeting C-reactive protein for the treatment of cardiovascular diseaseMark B. Pepys, Stephen P. Wood, Gideon M. Hirschfield et al.|Nature|2006Cited by 676
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic AcidGideon M. Hirschfield, Д. А. Шапиро, Andrew L. Mason et al.|Gastroenterology|2014Cited by 563
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitisJimmy Z. Liu, Tom H. Karlsen, Javier Gutierrez‐Achury et al.|Nature Genetics|2013Cited by 398
The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitisMarco Carbone, George Mells, Stephen J. Sharp et al.|Hepatology|2015Cited by 348